Amgen Inc . (NASDAQ:AMGN), a leading biotechnology company with a market capitalization of $151.3 billion, is navigating a ...

As Sandoz gears up to launch one of the most anticipated biosimilars of the year, the company could face near-term ...

Today, Benzinga 's options scanner spotted 28 uncommon options trades for Amgen. This isn't normal. The overall sentiment of ...

Situated in the core of the NC Research Triangle, the site at Camp Helix Innovation Park is a substantial regional investment ...

The U.S. Food and Drug Administration approved Amgen's combination therapy on Thursday to treat colorectal cancer in patients ...

As more United States drug price changes have come to light this month, it remains clear that companies are tamping down ...

The second round of Medicare Part D price negotiations will feature two drugs familiar to rheumatologists — Ofev and Otezla — ...

Amgen executives and employees, local and state elected dignitaries, and an assortment of other local economic development ...

The price to buy certain infused biosimilars can be three times higher than reimbursement, and the problem is growing.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Amgen has inaugurated its new drug substance facility in the US after announcing a $1bn further expansion at the North Carolina (NC) site to address increasing demand for its medicines.